Preclinical testing of the glycogen synthase kinase-3β inhibitor tideglusib for rhabdomyosarcoma

Narendra Bharathy, Matthew N. Svalina, Teagan P. Settelmeyer, Megan M. Cleary, Noah E. Berlow, Susan D. Airhart, Sunny Xiang, James Keck, James Hayden, Jack F. Shern, Atiya Mansoor, Melvin Lathara, Ganapati Srinivasa, David M. Langenau, Charles Keller

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Rhabdomyosarcoma (RMS) is the most common childhood soft tissue sarcoma. RMS often arise from myogenic precursors and displays a poorly differentiated skeletal muscle phenotype most closely resembling regenerating muscle. GSK3β is a ubiquitously expressed serine-threonine kinase capable of repressing the terminal myogenic differentiation program in cardiac and skeletal muscle. Recent unbiased chemical screening efforts have prioritized GSK3β inhibitors as inducers of myodifferentiation in RMS, suggesting efficacy as single agents in suppressing growth and promoting self-renewal in zebrafish transgenic embryonal RMS (eRMS) models in vivo. In this study, we tested the irreversible GSK3β-inhibitor, tideglusib for in vivo efficacy in patient-derived xenograft models of both alveolar rhabdomyosarcoma (aRMS) and eRMS. Tideglusib had effective on-target pharmacodynamic efficacy, but as a single agent had no effect on tumor progression or myodifferentiation. These results suggest that as monotherapy, GSK3β inhibitors may not be a viable treatment for aRMS or eRMS.

Original languageEnglish (US)
Pages (from-to)62976-62983
Number of pages8
JournalOncotarget
Volume8
Issue number38
DOIs
StatePublished - 2017

Fingerprint

Glycogen Synthase Kinase 3
Rhabdomyosarcoma
Alveolar Rhabdomyosarcoma
Skeletal Muscle
Embryonal Rhabdomyosarcoma
Protein-Serine-Threonine Kinases
Zebrafish
Heterografts
Sarcoma
Myocardium
Phenotype
Muscles
Growth
NP 031112
Neoplasms
Therapeutics

Keywords

  • GSK3β
  • Myodifferentiation
  • Patient-derived xenograft
  • Preclinical testing
  • Rhabdomyosarcoma

ASJC Scopus subject areas

  • Oncology

Cite this

Bharathy, N., Svalina, M. N., Settelmeyer, T. P., Cleary, M. M., Berlow, N. E., Airhart, S. D., ... Keller, C. (2017). Preclinical testing of the glycogen synthase kinase-3β inhibitor tideglusib for rhabdomyosarcoma. Oncotarget, 8(38), 62976-62983. https://doi.org/10.18632/oncotarget.18520

Preclinical testing of the glycogen synthase kinase-3β inhibitor tideglusib for rhabdomyosarcoma. / Bharathy, Narendra; Svalina, Matthew N.; Settelmeyer, Teagan P.; Cleary, Megan M.; Berlow, Noah E.; Airhart, Susan D.; Xiang, Sunny; Keck, James; Hayden, James; Shern, Jack F.; Mansoor, Atiya; Lathara, Melvin; Srinivasa, Ganapati; Langenau, David M.; Keller, Charles.

In: Oncotarget, Vol. 8, No. 38, 2017, p. 62976-62983.

Research output: Contribution to journalArticle

Bharathy, N, Svalina, MN, Settelmeyer, TP, Cleary, MM, Berlow, NE, Airhart, SD, Xiang, S, Keck, J, Hayden, J, Shern, JF, Mansoor, A, Lathara, M, Srinivasa, G, Langenau, DM & Keller, C 2017, 'Preclinical testing of the glycogen synthase kinase-3β inhibitor tideglusib for rhabdomyosarcoma', Oncotarget, vol. 8, no. 38, pp. 62976-62983. https://doi.org/10.18632/oncotarget.18520
Bharathy N, Svalina MN, Settelmeyer TP, Cleary MM, Berlow NE, Airhart SD et al. Preclinical testing of the glycogen synthase kinase-3β inhibitor tideglusib for rhabdomyosarcoma. Oncotarget. 2017;8(38):62976-62983. https://doi.org/10.18632/oncotarget.18520
Bharathy, Narendra ; Svalina, Matthew N. ; Settelmeyer, Teagan P. ; Cleary, Megan M. ; Berlow, Noah E. ; Airhart, Susan D. ; Xiang, Sunny ; Keck, James ; Hayden, James ; Shern, Jack F. ; Mansoor, Atiya ; Lathara, Melvin ; Srinivasa, Ganapati ; Langenau, David M. ; Keller, Charles. / Preclinical testing of the glycogen synthase kinase-3β inhibitor tideglusib for rhabdomyosarcoma. In: Oncotarget. 2017 ; Vol. 8, No. 38. pp. 62976-62983.
@article{60646b83da3c4818aee5df603e0840cf,
title = "Preclinical testing of the glycogen synthase kinase-3β inhibitor tideglusib for rhabdomyosarcoma",
abstract = "Rhabdomyosarcoma (RMS) is the most common childhood soft tissue sarcoma. RMS often arise from myogenic precursors and displays a poorly differentiated skeletal muscle phenotype most closely resembling regenerating muscle. GSK3β is a ubiquitously expressed serine-threonine kinase capable of repressing the terminal myogenic differentiation program in cardiac and skeletal muscle. Recent unbiased chemical screening efforts have prioritized GSK3β inhibitors as inducers of myodifferentiation in RMS, suggesting efficacy as single agents in suppressing growth and promoting self-renewal in zebrafish transgenic embryonal RMS (eRMS) models in vivo. In this study, we tested the irreversible GSK3β-inhibitor, tideglusib for in vivo efficacy in patient-derived xenograft models of both alveolar rhabdomyosarcoma (aRMS) and eRMS. Tideglusib had effective on-target pharmacodynamic efficacy, but as a single agent had no effect on tumor progression or myodifferentiation. These results suggest that as monotherapy, GSK3β inhibitors may not be a viable treatment for aRMS or eRMS.",
keywords = "GSK3β, Myodifferentiation, Patient-derived xenograft, Preclinical testing, Rhabdomyosarcoma",
author = "Narendra Bharathy and Svalina, {Matthew N.} and Settelmeyer, {Teagan P.} and Cleary, {Megan M.} and Berlow, {Noah E.} and Airhart, {Susan D.} and Sunny Xiang and James Keck and James Hayden and Shern, {Jack F.} and Atiya Mansoor and Melvin Lathara and Ganapati Srinivasa and Langenau, {David M.} and Charles Keller",
year = "2017",
doi = "10.18632/oncotarget.18520",
language = "English (US)",
volume = "8",
pages = "62976--62983",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals",
number = "38",

}

TY - JOUR

T1 - Preclinical testing of the glycogen synthase kinase-3β inhibitor tideglusib for rhabdomyosarcoma

AU - Bharathy, Narendra

AU - Svalina, Matthew N.

AU - Settelmeyer, Teagan P.

AU - Cleary, Megan M.

AU - Berlow, Noah E.

AU - Airhart, Susan D.

AU - Xiang, Sunny

AU - Keck, James

AU - Hayden, James

AU - Shern, Jack F.

AU - Mansoor, Atiya

AU - Lathara, Melvin

AU - Srinivasa, Ganapati

AU - Langenau, David M.

AU - Keller, Charles

PY - 2017

Y1 - 2017

N2 - Rhabdomyosarcoma (RMS) is the most common childhood soft tissue sarcoma. RMS often arise from myogenic precursors and displays a poorly differentiated skeletal muscle phenotype most closely resembling regenerating muscle. GSK3β is a ubiquitously expressed serine-threonine kinase capable of repressing the terminal myogenic differentiation program in cardiac and skeletal muscle. Recent unbiased chemical screening efforts have prioritized GSK3β inhibitors as inducers of myodifferentiation in RMS, suggesting efficacy as single agents in suppressing growth and promoting self-renewal in zebrafish transgenic embryonal RMS (eRMS) models in vivo. In this study, we tested the irreversible GSK3β-inhibitor, tideglusib for in vivo efficacy in patient-derived xenograft models of both alveolar rhabdomyosarcoma (aRMS) and eRMS. Tideglusib had effective on-target pharmacodynamic efficacy, but as a single agent had no effect on tumor progression or myodifferentiation. These results suggest that as monotherapy, GSK3β inhibitors may not be a viable treatment for aRMS or eRMS.

AB - Rhabdomyosarcoma (RMS) is the most common childhood soft tissue sarcoma. RMS often arise from myogenic precursors and displays a poorly differentiated skeletal muscle phenotype most closely resembling regenerating muscle. GSK3β is a ubiquitously expressed serine-threonine kinase capable of repressing the terminal myogenic differentiation program in cardiac and skeletal muscle. Recent unbiased chemical screening efforts have prioritized GSK3β inhibitors as inducers of myodifferentiation in RMS, suggesting efficacy as single agents in suppressing growth and promoting self-renewal in zebrafish transgenic embryonal RMS (eRMS) models in vivo. In this study, we tested the irreversible GSK3β-inhibitor, tideglusib for in vivo efficacy in patient-derived xenograft models of both alveolar rhabdomyosarcoma (aRMS) and eRMS. Tideglusib had effective on-target pharmacodynamic efficacy, but as a single agent had no effect on tumor progression or myodifferentiation. These results suggest that as monotherapy, GSK3β inhibitors may not be a viable treatment for aRMS or eRMS.

KW - GSK3β

KW - Myodifferentiation

KW - Patient-derived xenograft

KW - Preclinical testing

KW - Rhabdomyosarcoma

UR - http://www.scopus.com/inward/record.url?scp=85029799466&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85029799466&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.18520

DO - 10.18632/oncotarget.18520

M3 - Article

VL - 8

SP - 62976

EP - 62983

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 38

ER -